Skip to main content

Table 5 Parameters for hepatic function

From: Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C - a randomized trial

 

NGLCD

LFD

 

Baseline

12 months

Mean change

Baseline

12 months

Mean change

AST (IU/l)

48 (22–65.5)

40.5 (24.6-60.7)

−6.2 ± 18.2* [−11,1,-1.4]

58 (29.5-85.7)

47.5 (29–62)

−8.7 ± 21.6# [−14.8, -2.7]

ALT (IU/l)

57.5 (22–78)

42 (27.3-68)

−10.6 ± 19.8* [−15.9, -5.4]

67 (41.2-102)

46 (33–67.7)

−11.8 ± 32.2# [−20.8, -2.8]

GGT (IU/l)

46.5 (29–67.5)

39.5 (23.7-55)

−9 ± 16 * [−13.2, -4.8]

62 (45–76)

42 (35–61.5)

−12.1 ± 12.4# [−15.6, -8.6]

Albumin (g/dl)

4.3 ± 0.3

4.3 ± 0.3

0.06 ± 0.3 ** [−0.01,-0.14]

4.2 ± 0.4

4.2 ± 0.3

0.06 ± 0.3## [−0.02, 0.15]

AST/ALT

0.95 ± 0.37

0.96 ± 0.26

0.01-0.3 *** [−0.07,-0.09]

0.89 ± 0.31

0.92 ± 0.2

0.02 ± 0.32# [−.06, 0.12]

APRI

0.47 (0.3-0.82)

0.45 (0.27-0.69)

−0.1 ± 0.27* [−0.17, -0.03]

0.73 (0.31-0.93)

0.53 (0.28-0.71)

−0.13 ± 0.32### [−0.2, -0.1]

FI

5.5 ± 1.1

5.3 ± 1.1

−0.2 ± 0.35* [−0.29, -0.1]

5.5 ± 1.3

5.3 ± 1.3

−0.2 ± 0.31# [−0.3, -0.1]

  1. Values are means ± SD; for variables abnormally distributed we used median ± interquartile ranges (25th and 75th percentiles).
  2. All p >0.05 for difference between groups at baseline and 12 months; *, p < 0.05 for mean change baseline, 12 months; #, p < 0.05 for mean change baseline, 12 months; **, p = 0.295; ***, p = 0.925; ##, p = 0.539; ###, p = 0.108.
  3. NGLCD normoglucidic low-calorie diet, LFD low-fat diet, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma-glutamyl transpeptidase, APRI AST to platelet ratio index, FI Forns fibrosis index.